MailMyPrescriptions is a licensed and accredited US Pharmacy with the following Certifications:
Powered by GeniusRx
How does an FSA work?
Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Alcaftadine is used for the prevention of ocular itching associated with allergic conjunctivitis. Efficacy of alcaftadine for this use has been demonstrated in several controlled conjunctival antigen challenge studies in patients 10 years of age and older with allergic conjunctivitis. Results of these studies indicate that in patients with allergic conjunctivitis who were challenged with conjunctival antigen at 15 minutes and 16 hours after receiving alcaftadine 0.25% ophthalmic solution or vehicle, alcaftadine was more effective than vehicle in preventing ocular itching. The onset of action for alcaftadine was rapid, with an effect on ocular itching observed at 3 minutes after conjunctival antigen challenge.
Avoidance of allergen and other triggering factors (e.g., irritants) and application of cold compresses and lubricating eye drops are the initial means of managing allergic conjunctivitis. Drug therapy generally is reserved for use when such avoidance is not possible or is ineffective and can include both prophylactic (e.g., mast-cell stabilizers) and symptomatic (e.g., topical and/or systemic antihistamines, topical vasoconstrictors, topical steroid and nonsteroidal anti-inflammatory agents [NSAIAs]) therapy. The specific therapy(ies) employed will depend on the characteristics and severity of the allergic conjunctivitis. For patients with seasonal allergic conjunctivitis, prophylaxis with a mast-cell stabilizer often is initiated before and maintained throughout the pollen season, and symptomatic therapy with other agents (e.g., topical antihistamines, topical NSAIAs) generally is initiated as necessary to provide acute relief. Topical corticosteroids usually are reserved for short-term use in patients with moderate to severe symptoms of allergic conjunctivitis.
Dosage and Administration
Alcaftadine is applied topically to the eye as an ophthalmic solution. The ophthalmic solution is for topical ophthalmic use only. Care should be taken to avoid contamination of the solution container.
Alcaftadine ophthalmic solution contains benzalkonium chloride, which may be absorbed by some soft contact lenses. Patients should be advised to remove their contact lenses prior to administration of each dose of alcaftadine ophthalmic solution. Patients whose eyes are not red may reinsert soft contact lenses after 10 minutes following administration of the ophthalmic solution.
The recommended dosage of alcaftadine for the prevention of itching associated with allergic conjunctivitis in adults and children 2 years of age or older is 1 drop of a 0.25% solution in each eye once daily.
The manufacturer makes no special population recommendations at this time.
The manufacturer states that there are no known contraindications to the use of alcaftadine.
Alcaftadine ophthalmic solution is for topical ophthalmic use only. The ophthalmic solution should not be instilled while the patient is wearing contact lenses. Patients should be advised not to wear contact lenses if their eyes are red. The ophthalmic solution should not be used to treat contact lens-related irritation.(See Dosage and Administration: Administration.)
It is not known whether alcaftadine is distributed into milk following topical application to the eye. Because many drugs are distributed into milk, caution should be exercised when alcaftadine is used in nursing women.
Safety and efficacy of alcaftadine ophthalmic solution have not been established in children younger than 2 years of age. Pediatric patients 10 years of age or older were included in controlled clinical trials evaluating efficacy and safety of alcaftadine ophthalmic solution, and pediatric patients 3 years of age or older were included in environmental studies establishing safety of the drug. Efficacy of the drug in children 2-9 years of age was extrapolated from demonstrated efficacy in older children and adults.
No overall differences in safety or efficacy were observed between geriatric patients and younger patients.
Common Adverse Effects
The most common adverse ocular effects (reported in less than 4% of eyes treated with alcaftadine ophthalmic solution) include irritation, burning, and/or stinging upon instillation; redness; and pruritus. Common nonocular adverse effects (reported in less than 3% of patients receiving the drug) include nasopharyngitis, headache, and influenza.
No formal drug interaction studies have been performed to date.